Novel coumarin-quinoline ruthenium complexes, their synthesis methods and applications

By synthesizing a novel coumarin-quinoline ruthenium complex, the problems of toxicity and drug resistance of existing antitumor drugs were solved. It effectively inhibited drug-resistant human lung cancer cells and had low toxicity to normal cells, demonstrating superior antitumor activity and selectivity.

CN123106773APending Publication Date: 2026-11-17YULIN NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410566165.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-09
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing antitumor drugs such as cisplatin have shown toxic side effects and drug resistance problems with long-term use. The development of non-platinum metal antitumor drugs is of great significance, and research on the antitumor effects of ruthenium complexes, a coumarin derivative, has not yet been reported.

Method used

Novel coumarin-quinoline ruthenium complexes were synthesized by reacting cis-Ru(DMSO)4Cl2 with 5,7-dichloro-8-hydroxy-2-methylquinoline and then coumarin derivatives to prepare four novel complexes for anticancer experiments on drug-resistant human lung cancer cells.

Benefits of technology

The novel coumarin-quinoline ruthenium complex exhibits good inhibitory effects on drug-resistant human lung cancer cells and low toxicity to normal cells, demonstrating superior antitumor activity and selectivity, and possessing potential medicinal value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to novel coumarin-quinoline ruthenium complexes, their synthesis methods, and applications. The novel coumarin-quinoline ruthenium complexes are either complex 1 or complex 2. This invention uses cis-Ru(DMSO)4Cl2 as a metal salt to react with 5,7-dichloro-8-hydroxy-2-methylquinoline (H-QL1e), and then coordinates with coumarin derivatives to synthesize four novel coumarin-quinoline ruthenium complexes. Anticancer activity and toxicity experiments on human lung cancer drug-resistant cell line A549 / DDP and normal HEK293 cells revealed that the novel coumarin-quinoline ruthenium complexes of this invention have a good inhibitory effect on human lung cancer drug-resistant cell line A549 / DDP and very low toxicity to normal HEK293 cells. This invention demonstrates that the novel coumarin-quinoline ruthenium complex exhibits superior antitumor activity and good selectivity, possessing potential pharmaceutical value and promising for the preparation of various antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to novel coumarin-quinoline ruthenium complexes, their synthesis methods, and applications. Background Technology

[0002] A key characteristic of tumor cell development is the unchecked proliferative capacity of tumor cells, which are not regulated by the normal body. Therefore, inhibiting tumor cell growth or promoting tumor cell apoptosis is an important means of preventing tumor progression. The search for novel, highly effective, low-toxicity anti-tumor drugs that can directly target specific tumors has always been a persistent goal of humankind.

[0003] Cisplatin has the function of inhibiting tumor cell growth, and clinically, it has shown good therapeutic effects on solid tumors such as ovarian cancer, lung cancer, and bladder cancer. However, during long-term use, cisplatin's numerous toxic side effects, such as nephrotoxicity, ototoxicity, and neurotoxicity, gradually emerged. Simultaneously, some tumor cells developed resistance to cisplatin. Based on cisplatin, platinum-based drugs such as carboplatin and oxaliplatin were further developed. These drugs reduced the toxic side effects to some extent, but cross-resistance issues still exist, and they are ineffective against some tumor cells. Therefore, the development of non-platinum-based antitumor drugs is of great significance.

[0004] Coumarins are a class of natural compounds with a benzo-α-pyran structure, widely studied for their small molecular weight, simple synthesis, and high bioavailability. Numerous studies have shown that coumarins and their derivatives possess anti-inflammatory, antioxidant, antiviral, and antitumor effects. In recent years, metal-based antitumor drugs have gained increasing favor among researchers, who have begun to incorporate coumarin groups into metal drugs to enhance their antitumor activity.

[0005] In the existing technology, a series of coumarin platinum, palladium and other metal anticancer complexes have been reported, which have good anticancer effects on various tumor cells (Qin, Q.-P.; et al. European Journal of Medicinal Chemistry, 2019, 184, 111751.). Ruthenium complexes of coumarin derivatives have been reported in existing technologies. For example, Li Yanci et al. synthesized 11 coumarin β-diketone derivatives using salicylaldehyde and its derivatives as raw materials. Through coordination with [RuCl2(cym)]2, they obtained 11 class I arylruthenium(II) complexes. Further, by substituting Cl with perfluorooctylethyl imidazole, they obtained 11 class II arylruthenium(II) complexes. Cellular activity studies using the MTT assay revealed that class II arylruthenium(II) complexes exhibited good cytotoxicity against human cervical cancer cells, human breast cancer cells, human lung cancer cells, and human gastric cancer cells, while class I arylruthenium(II) complexes showed almost no cytotoxicity. Studies also showed that complexes with perfluorooctylethyl imidazole as the ligand exhibited significantly better cytotoxicity than the corresponding non-fluorinated alkyl imidazole complexes. Therefore, ruthenium complexes with different active ligands can exhibit different and unpredictable cytotoxicities against different tumor cells.

[0006] There are currently no reports on the antitumor effects of ruthenium complexes with coumarin derivatives as active ligands; the structural formulas of the aforementioned coumarin derivatives are as follows:

[0007] .

[0008] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention

[0009] The purpose of this invention is to provide novel coumarin-quinoline ruthenium complexes, their synthesis methods, and applications. The novel coumarin-quinoline ruthenium complexes provided have excellent antitumor activity and potential application value, and are expected to be used to prepare antitumor drugs.

[0010] To achieve the above objectives, the present invention provides the following technical solution:

[0011] The first objective of this invention is to provide a novel coumarin-quinoline ruthenium complex, wherein the novel coumarin-quinoline ruthenium complex is either complex 1 or complex 2; wherein the structural formula of complex 1 is as follows:

[0012] ;

[0013] The structural formula of the complex 2 is as follows:

[0014] ;

[0015] Where R3 is H or Cl; R4 is Cl or Br.

[0016] More specifically, the synthesis method of complex 1 is as follows: Weigh 0.2 mmol of the metal salt cis-Ru(DMSO)4Cl2 and 0.4 mmol of 5,7-dichloro-8-hydroxy-2-methylquinoline, add 1.5 mL of CH3OH, 0.5 mL of CH2Cl2 and 0.1 mL of triethylamine, react at 65 °C for 3 days, cool to room temperature, filter, and obtain rod-shaped red crystals, which is the complex 1.

[0017] The synthesis method of the complex 2 is as follows: Weigh 0.2 mmol of coumarin derivative H-QL3a–H-QL3c and 0.2 mmol of complex 1, add 2.0 mL of CH3OH, 0.5 mL of CH2Cl2 and 0.1 mL of triethylamine, react at 50-90℃ for 3 days, cool to room temperature, filter, and obtain rod-shaped black crystals, which is the complex 2.

[0018] A second objective of this invention is to provide the application of novel coumarin-quinoline ruthenium complexes in the preparation of antitumor drugs.

[0019] More specifically, the tumor in question is human lung cancer.

[0020] The third objective of this invention is to provide an in vitro and in vivo antitumor drug, wherein the novel coumarin-quinoline ruthenium complex is the active ingredient.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] This invention synthesizes four novel coumarin-quinoline ruthenium complexes by reacting cis-Ru(DMSO)4Cl2 as a metal salt with 5,7-dichloro-8-hydroxy-2-methylquinoline (H-QL1e) and then coagulating them with coumarin derivatives. Anticancer activity and toxicity experiments on the drug-resistant human lung cancer cell line A549 / DDP and normal HEK293 cells revealed that the novel coumarin-quinoline ruthenium complexes of this invention exhibit excellent inhibitory effects on the drug-resistant human lung cancer cell line A549 / DDP and low toxicity to normal HEK293 cells. This indicates that the novel coumarin-quinoline ruthenium complexes of this invention demonstrate superior antitumor activity and good selectivity, possessing potential pharmaceutical value and promising applications in the preparation of various antitumor drugs. Attached Figure Description

[0023] Figure 1This is the X-ray single-crystal structure diagram of compound YNU-4e;

[0024] Figure 2 The image shows the X-ray single-crystal structure of compound YNU-4f.

[0025] Figure 3 The image shows the X-ray single-crystal structure of compound YNU-4g.

[0026] Figure 4 This is the X-ray single-crystal structure diagram of compound YNU-4h. Detailed Implementation

[0027] The technical solution of this invention patent will be clearly and completely described below. Obviously, the described embodiments are some embodiments of this invention, but not all embodiments.

[0028] 1. Materials and Methods

[0029] 1.1 Synthesis of Coumarin Derivatives

[0030] Coumarin derivatives, denoted as H-QL3a, H-QL3b, and H-QL3c, were synthesized according to the methods described in Qin, Q.-P.; et al. European Journal of Medicinal Chemistry, 2019, 184, 111751 and Cadoni, E.; et al. J. Inorg. Biochem., 2017, 177, 101-109, and their structural formulas are as follows:

[0031] .

[0032] 1.2 Synthetic Complex 1

[0033] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of the metal salt cis-Ru(DMSO)4Cl2 and 0.4 mmol of 5,7-dichloro-8-hydroxy-2-methylquinoline (H-QL1e) were weighed. Then, 1.5 mL of CH3OH, 0.5 mL of CH2Cl2 and 0.1 mL of triethylamine (Et3N) were added. The drug-resistant bottle was capped and reacted at 65 °C for 3 days. After cooling to room temperature, the cap of the system was opened and the mixture was filtered to obtain rod-shaped reddish-brown crystals Ru(QL1e)2(DMSO)2, which is complex 1, denoted as YNU-4e, with a yield of 83.3%.

[0034] The synthetic route for complex 1 is as follows:

[0035]

[0036] 1.3 Synthetic Complex 2

[0037] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of coumarin derivatives H-QL3a, H-QL3b, or H-QL3c and an equimolar amount of YNU-4e (i.e., complex 1 synthesized in 1.2) were weighed. Then, 2.0 mL of CH3OH, 0.5 mL of CH2Cl2, and 0.1 mL of triethylamine (Et3N) were added. After capping the drug-resistant bottle, the mixture was reacted at 65 °C for 3 days. After cooling to room temperature, the cap of the system was opened, and the mixture was filtered to obtain rod-shaped black crystals, which were complex 2, and were designated as YNU-4f, YNU-4g, and YNU-4h, respectively, with yields of 43.8–61.0%.

[0038] The synthetic route for complex 2 is as follows:

[0039]

[0040] 1.4 Identification of Complex 1 and Complex 2

[0041] 1.4.1 X-ray Single Crystal

[0042] The X-ray single crystal structures of compounds YNU-4e, YNU-4f, YNU-4g, and YNU-4h are shown in [reference needed]. Figure 1-4 .

[0043] 1.4.2 Elemental Analysis

[0044] The results are shown in Table 1.

[0045]

[0046] 1.4.3 Infrared Spectrum

[0047] Data for YNU-4e. Yield: 83.3%. IR (KBr): 3937, 3439, 3019, 2917,1973, 1634, 1599, 1581, 1547, 1497, 1450, 1415, 1376, 1362, 1314, 1255, 1295,1281, 1255, 1198, 1154, 1109, 1087, 1024, 989, 970, 926, 871, 834, 823, 780,754, 722, 705, 682, 608, 538, 515, 504, 485, 453, 426 cm −1 .

[0048] Data for YNU-4f. Yield: 43.8%. IR (KBr): 3430, 3077, 2928, 2311,1699, 1597, 1580, 1545, 1497, 1479, 1415, 1361, 1315, 1281, 1254, 1228, 1197,1153, 1115, 1030, 1012, 965, 944, 877, 835, 823, 794, 780, 753, 705, 665,624, 608, 585, 538, 513, 504, 485, 455, 431 cm −1 。

[0049] Data for YNU-4g. Yield: 51.1%. IR (KBr): 3412, 3073, 2924, 1722,1690, 1592, 1578, 1563, 1545, 1497, 1476, 1465, 1445, 1413, 1360, 1315, 1281,1254, 1236, 1221, 1197, 1152, 1110, 1074, 1030, 985, 963, 940, 878, 861, 835,822, 817, 796, 781, 753, 704, 682, 664, 622, 614, 569, 540, 512, 504, 493 cm −1 。

[0050] Data for YNU-4h. Yield: 61.0%. IR (KBr): 3850, 3745, 3671, 3648,3442, 3077, 2927, 1941, 1690, 1596, 1580, 1567, 1546, 1497, 1479, 1465, 1449,1415, 1361, 1315, 1281, 1254, 1223, 1198, 1153, 1116, 1082, 1030, 987, 965,945, 877, 835, 822, 796, 781, 753, 706, 670, 664, 625, 607, 576, 539, 514,505, 493, 455, 432 cm −1 。

[0051] In summary, the structural formulas of compounds YNU-4e, YNU-4f, YNU-4g, and YNU-4h are determined as follows:

[0052]

[0053] 2. In vitro and in vivo antitumor activity experiments of complex 1 and complex 2

[0054] 2.1 Cell lines and cell culture

[0055] Two human cell lines were selected: A549 / DDP, a drug-resistant human lung cancer cell line, and HEK293, a normal human embryonic kidney cell line.

[0056] All human cell lines were cultured in RPMI-1640 medium containing 100 U / mL penicillin, 10 wt% fetal blood, and 100 U / mL streptomycin, and incubated at 37°C in an incubator containing 5% CO2 by volume.

[0057] 2.2 Preparation of the test compound

[0058] All compounds had a purity ≥95%. Their DMSO stock solutions were diluted with physiological buffer to a final solution of 20 mmol / L (final DMSO concentration ≤1%). The inhibitory effect of each compound on the growth of normal cells and selected tumor cells was then tested.

[0059] 2.3 Cell growth inhibition assay (using CCK-8 assay)

[0060] The specific steps are as follows:

[0061] S1. Cells are digested, counted, and prepared to a concentration of 5 × 10⁻⁶. 4 Add 100 μL of cell suspension per well to a 96-well cell culture plate and incubate at 37°C in a 5% CO2 incubator for 24 h.

[0062] S2. Dilute the drug to the required concentration using RPMI-1640 medium. Add 100 μL of the corresponding drug-containing medium to each well of a 96-well plate to achieve final concentrations of 0, 1.0, 2.5, 5.0, 10.0, and 20.0 μM, respectively. Set up 6 parallel experiments for each concentration. After adding the drug, incubate at 37℃ in a 5% CO2 incubator for 48 h. Use the 0 concentration as a control.

[0063] S3. Perform CCK-8 staining and measure OD values ​​at a wavelength of λ=450nm: Add 10μL of CCK-8 to each well, continue incubation for 2 hours, gently mix by shaking for 10 minutes, and then measure the OD value of each well at a wavelength of λ=450nm using a microplate reader. Calculate the inhibition rate of each compound on the growth of the selected cell lines, and then calculate the IC50 of each tested compound on the selected cell lines using the Bliss method. 50 Values. The results are shown in Table 2 below.

[0064]

[0065] As shown in Table 2, from IC 50 The results showed that compounds YNU-4e, YNU-4f, YNU-4g, and YNU-4h had a good inhibitory effect on the cisplatin-resistant human lung cancer cell line A549 / DDP, with an IC50 value of [missing information]. 50 The values ​​were 10.20±0.43µM, 1.75±0.09µM, 5.01±0.07µM and 3.49±0.22µM, respectively, which were much smaller than those of H-QL1e, H-QL3a, H-QL3b, H-QL3c, the metal salt cis-Ru(DMSO)4Cl2 and the clinical drug cisplatin; while the compounds YNU-4f, YNU-4g and YNU-4h were superior to compound YNU-4e.

[0066] In addition, the four compounds YNU-4e, YNU-4f, YNU-4g and YNU-4h showed very low toxicity to the normal HEK293 cell line, indicating that the novel coumarin-quinoline ruthenium complex of the present invention is selective for the human lung cancer cisplatin-resistant cell line A549 / DDP.

[0067] In summary, the novel coumarin-quinoline ruthenium complex of this invention exhibits superior antitumor activity and has potential pharmaceutical value, and is expected to be used in the preparation of various antitumor drugs.

[0068] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.

Claims

1. A novel coumarin-quinoline ruthenium complex, characterized in that, The novel coumarin-quinoline ruthenium complex is either complex 1 or complex 2; wherein, the structural formula of complex 1 is as follows: ; The structural formula of the complex 2 is as follows: ; Where R3 is H or Cl; R4 is Cl or Br.

2. The novel coumarin-quinoline ruthenium complex according to claim 1, characterized in that, The synthesis method of the complex 1 is as follows: Weigh 0.2 mmol of the metal salt cis-Ru(DMSO)4Cl2 and 0.4 mmol of 5,7-dichloro-8-hydroxy-2-methylquinoline, add 1.5 mL of CH3OH, 0.5 mL of CH2Cl2 and 0.1 mL of triethylamine, react at 65 °C for 3 days, cool to room temperature, filter, and obtain rod-shaped red crystals, which is the complex 1.

3. The novel coumarin-quinoline ruthenium complex according to claim 1, characterized in that, The synthesis method of the complex 2 is as follows: Weigh 0.2 mmol of coumarin derivative and 0.2 mmol of complex 1, add 2.0 mL of CH3OH, 0.5 mL of CH2Cl2 and 0.1 mL of triethylamine, react at 50-90℃ for 3 days, cool to room temperature, filter, and obtain rod-shaped black crystals, which is the complex 2.

4. The novel coumarin-quinoline ruthenium complex according to claim 3, characterized in that, The structural formula of the coumarin derivative is as follows: Where R3 is H or Cl; R4 is Cl or Br.

5. The use of the novel coumarin-quinoline ruthenium complex according to claim 1 in the preparation of antitumor drugs.

6. The application according to claim 5, characterized in that, The tumor is human lung cancer.

7. An in vitro and in vivo antitumor drug, characterized in that, The in vitro and in vivo antitumor drug uses the novel coumarin-quinoline ruthenium complex as described in claim 1 as its active ingredient.